Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis

Lee, Hyojeong, Jeong, Gwang Hun, Li, Han, Kim, Min Seo, Kim, Jae Seok, Park, Se Jin, Han, Young Joo, Lee, Keum Hwa, Kronbichler, Andreas, Hong, Sung Hwi, Ghayda, Ramy A., Luchini, Claudio, Nottegar, Alessia, Koyanagi, Ai, Smith, Lee, Jacob, Louis, Dragioti, Elena, Radua, Joaquim, Cargnin, Sarah, Terrazzino, Salvatore, Thompson, Trevor, Yon, Dong Keon, Lee, Seung Won, Yang, Jee Myung, Wasuwanich, Paul, Shin, Jae Il and Gamerith, Gabriele (2021) Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences, 25 (20). pp. 6232-6244. ISSN 2284-0729

Preview	Text Published Version Available under the following license: Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview
	Text Accepted Version Restricted to Repository staff only Available under the following license: Creative Commons Attribution Non-commercial No Derivatives. Download (586kB) | Request a copy

Abstract

OBJECTIVE: It is controversial whether there is efficacy or safety benefit of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell lung cancer (NSCLC) compared to standard chemotherapy. We aim to assess the efficacy and safety of EGFR-TKIs compared to other chemotherapeutics in EGFR-mutated NSCLC. MATERIALS AND METHODS: Up to April 27th, 2020, PubMed, Embase, Medline, Scopus, Cochrane library, and ClinicalTrials.gov were searched for articles or trials meeting the inclusion criteria. After filtering, 230 eligible studies were initially identified. Data extraction followed PRISMA and included outcomes were progression-free survival (PFS), overall survival (OS), and severe adverse events (SAEs). Direct and indirect meta-analyses were generated in the context of log-linear mixed-effects models, with fixed effects for each relative comparison and random effects for each study. RESULTS: The results showed that EGFR-TKI therapy had improved PFS with a hazard ratio (HR) of 0.40 (95% CI: 0.36-0.44, p<0.001) compared to standard chemotherapy. Nevertheless, the EGFR-TKIs showed no benefit on OS (HR: 0.96, 95% CI: 0.83-1.10, p=0.556). In the analysis of adverse events, EGFR-TKIs had fewer SAEs than standard chemotherapy (HR: 0.29, 95% CI: 0.26-0.33, p<0.001). CONCLUSIONS: Our systemic review indicates that EGFR-TKI therapy has improved PFS, and reduced SAEs compared to standard chemotherapy in advanced EGFR-mutated NSCLC.

Item Type:	Journal Article
Keywords:	Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor, Tyrosine Kinase, Meta-Analysis
Faculty:	Faculty of Science & Engineering
SWORD Depositor:	Symplectic User
Depositing User:	Symplectic User
Date Deposited:	06 Apr 2021 14:43
Last Modified:	02 Nov 2021 09:27
URI:	https://arro.anglia.ac.uk/id/eprint/706477

Actions (login required)

Edit Item